JP2007504142A5 - Ｈｉｖプロテアーゼ阻害薬固体分散物を含む固体薬物剤形 - Google Patents

Ｈｉｖプロテアーゼ阻害薬固体分散物を含む固体薬物剤形 Download PDF

Info

Publication number
JP2007504142A5
JP2007504142A5 JP2006524782A JP2006524782A JP2007504142A5 JP 2007504142 A5 JP2007504142 A5 JP 2007504142A5 JP 2006524782 A JP2006524782 A JP 2006524782A JP 2006524782 A JP2006524782 A JP 2006524782A JP 2007504142 A5 JP2007504142 A5 JP 2007504142A5
Authority
JP
Japan
Prior art keywords
dosage form
solid
protease inhibitor
hiv protease
drug dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006524782A
Other languages
English (en)
Other versions
JP4815348B2 (ja
JP2007504142A (ja
Filing date
Publication date
Priority claimed from US10/650,178 external-priority patent/US20050048112A1/en
Application filed filed Critical
Publication of JP2007504142A publication Critical patent/JP2007504142A/ja
Publication of JP2007504142A5 publication Critical patent/JP2007504142A5/ja
Application granted granted Critical
Publication of JP4815348B2 publication Critical patent/JP4815348B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2006524782A 2003-08-28 2004-08-23 Ｈｉｖプロテアーゼ阻害薬固体分散物を含む固体薬物剤形 Active JP4815348B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/650,178 2003-08-28
US10/650,178 US20050048112A1 (en) 2003-08-28 2003-08-28 Solid pharmaceutical dosage form
PCT/US2004/027401 WO2005039551A2 (en) 2003-08-28 2004-08-23 Solid pharmaceutical dosage form comprising an hiv protease inhibitor solid dispersion

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2011032972A Division JP5498411B2 (ja) 2003-08-28 2011-02-18 固体薬物剤形
JP2011149721A Division JP5395125B2 (ja) 2003-08-28 2011-07-06 固体薬物剤形

Publications (3)

Publication Number Publication Date
JP2007504142A JP2007504142A (ja) 2007-03-01
JP2007504142A5 true JP2007504142A5 (ja) 2007-10-04
JP4815348B2 JP4815348B2 (ja) 2011-11-16

Family

ID=34217089

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2006524782A Active JP4815348B2 (ja) 2003-08-28 2004-08-23 Ｈｉｖプロテアーゼ阻害薬固体分散物を含む固体薬物剤形
JP2011032972A Active JP5498411B2 (ja) 2003-08-28 2011-02-18 固体薬物剤形
JP2011149721A Active JP5395125B2 (ja) 2003-08-28 2011-07-06 固体薬物剤形
JP2013168001A Active JP5903413B2 (ja) 2003-08-28 2013-08-13 固体薬物剤形
JP2015237449A Withdrawn JP2016094433A (ja) 2003-08-28 2015-12-04 固体薬物剤形
JP2017173733A Pending JP2018035163A (ja) 2003-08-28 2017-09-11 固体薬物剤形

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2011032972A Active JP5498411B2 (ja) 2003-08-28 2011-02-18 固体薬物剤形
JP2011149721A Active JP5395125B2 (ja) 2003-08-28 2011-07-06 固体薬物剤形
JP2013168001A Active JP5903413B2 (ja) 2003-08-28 2013-08-13 固体薬物剤形
JP2015237449A Withdrawn JP2016094433A (ja) 2003-08-28 2015-12-04 固体薬物剤形
JP2017173733A Pending JP2018035163A (ja) 2003-08-28 2017-09-11 固体薬物剤形

Country Status (31)

Country Link
US (1) US20050048112A1 (ja)
EP (6) EP1663183B9 (ja)
JP (6) JP4815348B2 (ja)
KR (5) KR101563222B1 (ja)
CN (5) CN101919858B (ja)
AT (1) ATE516017T1 (ja)
AU (3) AU2004283087C1 (ja)
CA (2) CA2536638C (ja)
CR (3) CR8256A (ja)
CY (5) CY1111981T1 (ja)
DK (5) DK2258344T3 (ja)
EA (4) EA020992B1 (ja)
EC (1) ECSP066397A (ja)
ES (5) ES2653762T3 (ja)
HK (4) HK1094766A1 (ja)
HR (1) HRP20110555T1 (ja)
HU (3) HUE031153T2 (ja)
IL (3) IL173939A (ja)
ME (2) MEP17608A (ja)
MX (2) MX358033B (ja)
NO (3) NO330282B1 (ja)
NZ (2) NZ579622A (ja)
PL (5) PL2258346T3 (ja)
PT (5) PT2258344E (ja)
RS (2) RS59969B1 (ja)
SG (3) SG145690A1 (ja)
SI (5) SI1663183T1 (ja)
TW (1) TWI342221B (ja)
UA (1) UA85564C2 (ja)
WO (1) WO2005039551A2 (ja)
ZA (3) ZA200801362B (ja)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034119A2 (en) * 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
AU2012202831B2 (en) * 2005-02-23 2015-01-22 Abbvie Inc. A solid pharmaceutical dosage formulation
KR20070025070A (ko) * 2005-08-31 2007-03-08 주식회사 대웅제약 시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법
AU2006325404B2 (en) * 2005-12-14 2012-03-01 Cipla Limited Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
EP1962808B1 (en) * 2005-12-14 2010-09-29 F. Hoffmann-La Roche AG Hcv prodrug formulation
US20090136570A1 (en) * 2006-01-20 2009-05-28 Bhagwant Rege Taste-Masked Tablets and Granules
EP1832281A1 (en) * 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
US20100173921A1 (en) * 2006-08-10 2010-07-08 Cipla Limited Antiretroviral Solid Oral Composition
US20080181948A1 (en) 2006-11-15 2008-07-31 Abbott Laboratories Solid pharmaceutical dosage formulations
ES2603617T3 (es) 2007-02-23 2017-02-28 Gilead Sciences, Inc. Moduladores de propiedades farmacocinéticas de la terapéutica
GT200800303A (es) * 2007-12-24 2009-09-18 Combinacion anti-retroviral
ES2607814T3 (es) * 2008-02-28 2017-04-04 Abbvie Inc. Preparación de tabletas
WO2009153654A1 (en) * 2008-06-17 2009-12-23 Aurobindo Pharma Limited Solid dosage forms of antiretrovirals
EP2346495B2 (en) * 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
WO2010070611A1 (en) 2008-12-18 2010-06-24 Ranbaxy Laboratories Limited Atazanavir formulations
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
US20110034489A1 (en) 2009-07-31 2011-02-10 Ranbaxy Laboratories Limited Solid dosage forms of hiv protease inhibitors
WO2011013110A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Unit dosage forms of hiv protease inhibitors
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA2829186A1 (en) * 2011-03-07 2012-09-13 Bandi Parthasaradhi Reddy Amorphous form of lopinavir and ritonavir mixture
WO2012164575A2 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
IN2014CN00827A (ja) * 2011-08-16 2015-04-03 Merck Sharp & Dohme
EP2564832A1 (en) 2011-08-29 2013-03-06 Hexal AG Solid dosage form of HIV protease inhibitors
KR101794032B1 (ko) * 2011-09-21 2017-11-07 (주)바이오시네틱스 나노입자 제조방법
ES2587559T3 (es) 2012-03-07 2016-10-25 Ratiopharm Gmbh Forma farmacéutica que comprende lopinavir y ritonavir
WO2013131645A1 (en) 2012-03-07 2013-09-12 Ratiopharm Gmbh Dosage form comprising non-crystalline lopinavir and crystalline ritonavir
CN103655571B (zh) * 2012-09-11 2016-04-20 上海星泰医药科技有限公司 一种洛匹那韦和利托那韦复方高均匀度纳米共分散体及其制备方法
EP2911651B1 (en) 2012-09-27 2016-06-22 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
US9744240B2 (en) 2012-09-27 2017-08-29 Basf Se Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer
US9789063B2 (en) 2012-09-27 2017-10-17 Basf Se Storage-stable dust-free homogeneous particulate formulation
CN104661652B (zh) 2012-09-27 2018-08-28 巴斯夫欧洲公司 包含至少一种水溶性维生素e衍生物和至少一种亲水聚合物的储存稳定的无粉尘均质颗粒状配制剂
RU2505286C1 (ru) 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
RU2543322C1 (ru) * 2013-09-19 2015-02-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
RU2619840C1 (ru) * 2016-09-21 2017-05-18 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция для лечения ВИЧ-инфекции
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
US20190038754A1 (en) * 2017-08-07 2019-02-07 SE Tylose, USA, Inc. Pharmaceutical composition in solid extruded form
EP3758683A1 (en) * 2018-03-02 2021-01-06 The University Of Liverpool Solid compositions of actives, processes for preparing same and uses of such solid compositions
CN108186578A (zh) * 2018-03-27 2018-06-22 聊城大学 一种利托那韦固体分散体的制备方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
TWI799599B (zh) * 2019-06-06 2023-04-21 華納國際生物科技股份有限公司 醫藥或保健品自乳化固體分散組成物
CN114146061B (zh) * 2020-09-07 2023-06-30 歌礼生物科技（杭州）有限公司 包含固体分散体的蛋白酶抑制剂增效组合物及其制备方法
CN113318076B (zh) * 2021-06-02 2022-09-23 聊城大学 一种兼具增溶及抑晶效果的利托那韦固体分散体及其制备方法
CN114557967B (zh) * 2022-03-17 2023-06-02 乐普制药科技有限公司 一种利托那韦固体分散体的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525108B1 (fr) 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
US5552558A (en) * 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5542206A (en) 1994-10-11 1996-08-06 Lisch; Albert Lure and tackle stacking container
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
DE19841244A1 (de) * 1998-09-09 2000-03-16 Knoll Ag Verfahren und Vorrichtung zum Herstellen von Tabletten
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
DE19913606A1 (de) 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
EP1733725B2 (en) 1999-06-04 2012-08-08 Abbott Laboratories Pharmaceutical solution comprising ritonavir, a solvent (long chain fatty acid) and water
EP1227797B1 (en) 1999-11-12 2005-01-12 Abbott Laboratories Solid dispersion pharmaceutical formulations
WO2001034119A2 (en) * 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
EP1401503B1 (en) 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer
BR0307344A (pt) * 2002-02-01 2004-12-14 Pfizer Prod Inc Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica
DE10213242A1 (de) * 2002-03-25 2003-10-16 Abbott Gmbh & Co Kg Testsystem zur Evaluierung der Kompatibilität biologisch aktiver Substanzen mit Copolymeren
DE10247037A1 (de) * 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US20080181948A1 (en) 2006-11-15 2008-07-31 Abbott Laboratories Solid pharmaceutical dosage formulations

Similar Documents

Publication Publication Date Title
JP2007504142A5 (ja) Ｈｉｖプロテアーゼ阻害薬固体分散物を含む固体薬物剤形
NO20064555L (no) HIV-integraseinhibitorer.
ATE461202T1 (de) Hiv-integrasehemmer
MA28489B1 (fr) Preparations pharmaceutiques
DE602005026188D1 (de) Medikamentenspender
BRPI0511900A (pt) composições farmacêuticas
CY2014011I1 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
TW200716119A (en) A solid pharmaceutical dosage formulation
NO20075628L (no) Farmasøytiske formuleringer
DK2384754T3 (da) Farmaceutiske doseringsformer
DK1957073T3 (da) Lægemiddel
DK2033629T3 (da) Fast farmaceutisk sammensætning omfattende valsartan
NL1028193A1 (nl) Farmaceutisch werkzame verbindingen.
DK1757293T3 (da) Bh4-responsiv hyperphenylalaninæmi-medikamenter
ATE429417T1 (de) Hiv-protease-inhibitoren
DK2918286T3 (da) En farmaceutisk formulering
DK1798234T3 (da) Farmaceutisk sammensætning omfattende temozolomidester
EP1855672A4 (en) HIV PROTEASE INHIBITORS
MA28603B1 (fr) Composition pharmaceutique antimycobacterienne
DK1784174T3 (da) Famaceutisk sammensætning omfattende gabapentin
ITMI20040943A1 (it) Composizione farmaceutica cicatrizzante
DK1753431T3 (da) Farmaceutisk sammensætning omfattende ZD6474
UA10369S (uk) Таблетка фармацевтична
SE0402678D0 (sv) Pharmaceutical use
SE0402639D0 (sv) Pharmaceutical use